Insulin Lispro (Humalog)

Insulin lispro was the first insulin analog ever approved — a genetically re-engineered version of the human hormone, cleared by the FDA in 1996, that absorbs faster than regular human insulin because two amino acids were deliberately swapped. It's also the single insulin product most closely tied to the US pricing crisis this site's main Insulin page describes: a list price that rose more than tenfold between 1996 and the late 2010s, the death of a 26-year-old Minnesotan who rationed it, and the state law and half-price authorized generic that followed.

The first insulin analog ever approved

This site's Insulin page covers Humulin, the first genetically-engineered drug of any kind (1982) — human-sequence insulin produced in bacteria instead of extracted from animal pancreases. Insulin lispro, marketed by Eli Lilly as Humalog, went a step further: instead of copying the natural human insulin sequence, Lilly deliberately altered it, swapping the order of two amino acids near the end of the insulin B-chain. The FDA approved Humalog on 14 June 1996 (NDA 020563) for adults and children with diabetes — the first "insulin analog" ever approved anywhere, meaning the first insulin product whose amino acid sequence differs on purpose from the human hormone it's based on, specifically to change how it behaves in the body rather than what it does once it gets there.

Swapping two amino acids to absorb faster

Regular human insulin naturally clusters into six-molecule hexamers in solution, which have to break apart into individual monomers before the body can absorb them — a process that delays onset by 30-60 minutes and stretches action out over several hours, timing that doesn't match how quickly a meal raises blood glucose. Insulin lispro reverses the order of two amino acids at positions B28 and B29 of the insulin chain (proline and lysine swap places), which disrupts the hydrophobic contacts that hold hexamers together without changing the hormone's ability to bind the insulin receptor. The result is an insulin that dissociates into monomers far faster after injection, producing a more rapid onset (roughly 15 minutes) and shorter duration of action (three to five hours) than regular human insulin. The pivotal evidence came from a randomized, open-label, six-month crossover trial across 17 countries and 102 investigators, enrolling 1,008 people with type 1 diabetes, comparing mealtime lispro to regular human insulin: lispro produced significantly lower post-meal glucose spikes and about 12% fewer hypoglycemia episodes over the study period (Anderson JH Jr, Brunelle RL, Koivisto VA, et al., for the Multicenter Insulin Lispro Study Group, "Reduction of Postprandial Hyperglycemia and Frequency of Hypoglycemia in IDDM Patients on Insulin-Analog Treatment," Diabetes 1997;46(2):265-270, PMID 9000704).¹

From $21 to $275 a vial — and the death that became a law

Humalog's US list price rose from roughly $21 a vial at its 1996 launch to more than $275 by the late 2010s, a trajectory that tracked the broader insulin-pricing crisis this site's Insulin page describes rather than anything specific to lispro's own manufacturing cost. That crisis had a name attached to it: Alec Smith, a 26-year-old Minneapolis restaurant manager who aged off his mother's health insurance in mid-2017, could not afford roughly $1,300 a month in insulin and supplies on his salary, began rationing his prescribed Humalog, and was found dead of diabetic ketoacidosis on 27 June 2017. His mother's advocacy afterward helped drive the Alec Smith Insulin Affordability Act, signed into Minnesota law in April 2020 and effective 1 July 2020 — the first program in the country guaranteeing a low-cost emergency insulin supply (a $35 one-time 30-day supply, with a $50 90-day option for longer-term need) to anyone who couldn't otherwise afford it. Separately, a large number of lawsuits against Eli Lilly, Novo Nordisk, Sanofi and several pharmacy-benefit managers (including CVS Caremark, Express Scripts and OptumRx) — alleging a scheme of rising list prices paired with rising manufacturer rebates to PBMs, with patients billed off the inflated list price, and asserting consumer-protection, unjust-enrichment and, in some suits, civil-conspiracy claims rather than federal antitrust claims — were centralized for coordinated pretrial proceedings in the District of New Jersey by the Judicial Panel on Multidistrict Litigation on 18 August 2023 (In re Insulin Pricing Litigation, MDL No. 3080), a docket that includes Humalog among the products named.

Cheaper alternatives: an authorized generic and a competitor's follow-on

Two real, FDA-sanctioned lower-cost alternatives to branded Humalog now exist. In March 2019, facing sustained public criticism over Humalog's price, Lilly announced an "authorized generic" — chemically identical insulin lispro sold under the plain name Insulin Lispro Injection at $137.35 per vial, roughly half of Humalog's list price at the time, available starting mid-2019 without a new prescription for existing Humalog patients. Separately, Sanofi developed its own insulin lispro product independent of Lilly's formula: the FDA approved Admelog (insulin lispro injection) on 11 December 2017, the first "follow-on" rapid-acting insulin lispro product cleared through the abbreviated 505(b)(2) pathway, based on a clinical program of more than 1,000 patients with type 1 or type 2 diabetes and priced below Humalog's list price. Neither product is a formal FDA biosimilar in the modern sense — that pathway didn't yet apply to insulin when either was approved — but both function as real, substitutable lower-cost mealtime insulin lispro options.

Current status

Humalog remains actively marketed by Eli Lilly in the US and internationally, in vials, cartridges and prefilled KwikPen devices, alongside Lilly's own authorized generic and Sanofi's Admelog. As described on this site's Insulin page, Humalog is also one of the specific products named in the 2025-2026 "most-favored-nation" manufacturer pricing agreements, with insulin lispro cited as low as $25 per month under the federal TrumpRx direct-purchase platform launched 5 February 2026 — a further, still-recent step in a pricing story that runs from a $21 launch price in 1996 through a well-documented rationing death in 2017 to a federally brokered $25 price nearly three decades later.